Sunday, April 14

Add-On Fruquintinib Delays Progression in Gastric Cancer

TOPLINE:

In clients with stomach or gastroesophageal cancer who have actually advanced on frontline chemotherapy, including fruquintinib to paclitaxel substantially postpones development however stops working to enhance general survival, brand-new stage 3 information revealed.

METHOD:

  • Second-line treatment choices for clients with stomach or gastroesophageal cancer are restricted to chemotherapy with or without ramucirumab, leaving an immediate requirement for alternative treatment choices.
  • The stage 3 double-blind, placebo-controlled FRUTIGA trial registered 703 clients with stomach or gastroesophageal cancer who had actually advanced on fluoropyrimidine- or platinum-containing chemotherapy.
  • Clients were arbitrarily appointed 1:1 to get fruquintinib with paclitaxel or placebo with paclitaxel up until illness development. Nearly all clients were Asian.
  • Main endpoints were progression-free survival (PFS) and total survival; secondary endpoints were total action rate, illness control rate, period of reaction, security, and lifestyle.

TAKEAWAY:

  • Clients in the fruquintinib group had substantially much better PFS than those in the placebo group (5.6 months vs 2.7 months; danger ratio [HR]0.57). Practically 2 times as lots of clients getting fruquintinib had a general action rate (42.5% vs 22.4%).
  • Clients getting fruquintinib did not show a substantial general survival advantage over the mean research study follow-up of 31.7 months. Average total survival was 1.2 months longer in the fruquintinib group (9.6 months vs 8.4 months; HR, 0.96; P =.6064).
  • When taking a look at a subgroup of clients with lymph node metastases and non-diffuse histology, those getting fruquintinib did reveal a small however substantial total survival advantage with an average total survival distinction of 1.7 months (9.6 vs 7.9 months; HR, 0.77; P =.0233). The scientists likewise kept in mind a small however substantial general survival advantage in the fruquintinib group after changing for subsequent anticancer treatment and standard qualities (HR variety, 0.79-0.83; P variety =.0105 -.0350).
  • Treatment-emergent grade 3 or greater unfavorable occasion rates were 86.9% in the fruquintinib arm vs 63.3 % in the placebo group. The most typical grade 3 plus negative occasions were neutropenia (60.0% vs 36.4%), leukopenia (42.9% vs 23.5%), and anemia (11.7% vs 10.6%).

IN PRACTICE:

“Fruquintinib plus paclitaxel might be an appealing second-line treatment choice for clients with innovative gastric/gastroesophageal adenocarcinoma who have actually stopped working fluoropyrimidine or platinum chemotherapy,” lead research study author Rui-hua Xu, MD, PhD, from Sun Yat-sen University Cancer Center in Guangzhou, China, stated in a news release.

SOURCE:

This research study, led by Rui-Hua Xu, MD, PhD, Sun Yat-sen University Cancer Center, existed at the ASCO Plenary Series on February 6, 2024, and at the same time released in the Journal of Clinical Oncology

RESTRICTIONS:

Nearly all clients registered were Asians, restricting generalizability. An active comparator was not utilized. Details on subsequent treatments, growth biology, and biomarkers was not offered.

DISCLOSURES:

This research study was sponsored by Hutchison Medipharma Limited. Xu stated getting consulting/advisory charges beyond this work.

ยป …
Find out more